Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BCTXL | PRESS-RELEASE | neutral | 3/10 | BriaCell Therapeutics held its annual shareholder meeting on March 5, 2026, reappointing auditors and electing directors | Mar 5, 2026 |
| CAMP | PRESS-RELEASE, 8-K | bullish | 7/10 | CAMP4 Therapeutics reported its 2025 financial results and provided corporate updates, including the advancement of its | Mar 5, 2026 |
| GEVO | PRESS-RELEASE | bullish | 7/10 | Gevo reported strong financial and operational performance for Q4 and full year 2025, highlighted by $45M in quarterly r | Mar 5, 2026 |
| AVBP | PRESS-RELEASE | mixed | 6/10 | ArriVent BioPharma reported its 2025 financial results, highlighting clinical progress with its lead asset firmonertinib | Mar 5, 2026 |
| ATYR | PRESS-RELEASE | mixed | 6/10 | aTyr Pharma reported full-year 2025 financial results and provided a clinical update, including that its Phase 3 EFZO-FI | Mar 5, 2026 |
| CRVS | PRESS-RELEASE | neutral | 3/10 | Corvus Pharmaceuticals announced plans to host a conference call on March 12, 2026, to discuss its fourth quarter 2025 f | Mar 5, 2026 |
| TVGN | PRESS-RELEASE | neutral | 4/10 | Tevogen Bio (TVGN) announced a non-binding Letter of Intent to evaluate a potential acquisition of Apozeal Pharmaceutica | Mar 5, 2026 |
| EVAX | PRESS-RELEASE | bullish | 8/10 | Evaxion reported strong 2025 financial and clinical progress, highlighted by a $7.5M upfront from MSD for its AI-discove | Mar 5, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion delayed the filing and publication of its 2025 annual report due to technical issues with external vendors, not | Mar 5, 2026 |
| ALGS | PRESS-RELEASE | mixed | 6/10 | Aligos Therapeutics reported financial results for Q4 and full year 2025, showing a大幅 reduction in net loss from the pri | Mar 5, 2026 |
| CRMD | PRESS-RELEASE | bullish | 8/10 | CorMedix reported strong Q4 and full-year 2025 results, driven by $128.6M in revenue (up 312% YoY) and $163.1M net incom | Mar 5, 2026 |
| CMPX | 8-K, PRESS-RELEASE | mixed | 7/10 | Compass Therapeutics reported its 2025 financial results and provided a corporate update, highlighting progress in its c | Mar 5, 2026 |
| HELP | PRESS-RELEASE | bullish | 8/10 | Helus Pharma announced positive topline results from a Phase 2 signal detection study of HLP004, an investigational intr | Mar 5, 2026 |
| MDCX | PRESS-RELEASE | bullish | 8/10 | Medicus Pharma (MDCX) announced positive topline results from its Phase 2 SKNJCT-003 trial of D-MNA, a microneedle patch | Mar 5, 2026 |
| IVVD | PRESS-RELEASE | bullish | 8/10 | Invivyd reported strong Q4 and full-year 2025 financial results with PEMGARDA net product revenue of $17.2 million (up 2 | Mar 5, 2026 |
| ERAS | PRESS-RELEASE | mixed | 5/10 | Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate its pan-RAS molecular glue ER | Mar 5, 2026 |
| IMTX | PRESS-RELEASE | neutral | 5/10 | Immatics reported full-year 2025 financial results with a significant revenue decline to $56.8 million and a net loss of | Mar 5, 2026 |
| MDWD | PRESS-RELEASE | bearish | 6/10 | MediWound reported a decline in Q4 and full-year 2025 revenue, driven by lower development services due to the U.S. gove | Mar 5, 2026 |
| GHRS | PRESS-RELEASE | bullish | 8/10 | GH Research reported financial results for 2025, highlighted by a strong Phase 2b trial for GH001 in treatment-resistant | Mar 5, 2026 |
| ALT | PRESS-RELEASE | bullish | 8/10 | Altimmune reported its Q4 and full-year 2025 financial results, highlighted by a strengthened balance sheet with $274 mi | Mar 5, 2026 |
| TNGX | PRESS-RELEASE | mixed | 6/10 | Tango Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $343.1 | Mar 5, 2026 |
| LXRX | PRESS-RELEASE | mixed | 6/10 | Lexicon Pharmaceuticals reported Q4 and full-year 2025 financial results with significantly reduced net loss and lower o | Mar 5, 2026 |
| CLYM | PRESS-RELEASE | neutral | 5/10 | Climb Bio reported Q4 and full-year 2025 financial results, highlighting a cash position of $160.7 million with runway i | Mar 5, 2026 |
| KURA | PRESS-RELEASE | bullish | 8/10 | Kura Oncology reported Q4 and full-year 2025 financial results, highlighted by $2.1 million in net product revenue from | Mar 5, 2026 |
| LQDA | PRESS-RELEASE | bullish | 8/10 | Liquidia Technologies reported strong full-year 2025 financial results driven by $148.3 million in net product sales of | Mar 5, 2026 |
| STTK | PRESS-RELEASE | neutral | 5/10 | Shattuck Labs reported financial results for Q4 and full year 2025, showing reduced net losses and R&D expenses due to p | Mar 5, 2026 |
| HCM | PRESS-RELEASE | mixed | 6/10 | HUTCHMED reported mixed financial results for 2025, with a significant $457 million net income driven by a $416 million | Mar 5, 2026 |
| SCYX | PRESS-RELEASE | bullish | 8/10 | Scynexis reported a significant year-over-year revenue increase to $20.6 million in 2025, driven by a $24.8 million one- | Mar 4, 2026 |
| ALTO | PRESS-RELEASE | bullish | 8/10 | Alto Ingredients (ALTO) reported strong Q4 and full-year 2025 results, driven by improved gross profit, a swing to net i | Mar 4, 2026 |
| ICCC | PRESS-RELEASE | mixed | 6/10 | ImmuCell reported a 4.3% increase in 2025 product sales to $27.6 million and a significant improvement in gross margin t | Mar 4, 2026 |